SCHEMBL8250652

SCHEMBL8250652

CC(C)Cc1ccc(C(=O)N2CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
HDAC4 P56524 1/20 0.50
ABL1 P00519 1/20 0.49
RIN1 Q13671 1/20 0.49
EPHX2 P34913 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
CYP2C19 P33261 1/20 0.47
MGLL Q99685 1/20 0.47
HTT P42858 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HRH3 Q9Y5N1 2/20 0.46
CNR2 P34972 1/20 0.46
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
SETD7 Q8WTS6 1/20 0.46
POLB P06746 2/20 0.45
GAA P10253 1/20 0.45
GPR119 Q8TDV5 1/20 0.45
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7387226 0.85 KMT2A (0.56) MEN1KMT2AHDAC4ABL1RIN1
SCHEMBL7324837 0.85 KMT2A (0.56) MEN1KMT2AHDAC4ABL1RIN1
SCHEMBL8427895 0.85 KMT2A (0.65) MEN1KMT2AHDAC4ABL1RIN1
SCHEMBL22550052 0.84 VEGFA (0.53) MEN1KMT2ASMN1; SMN2MGLLHTT
SCHEMBL2251044 0.84 KMT2A (0.67) MEN1KMT2AHDAC4ABL1RIN1
SCHEMBL5735314 0.84 MEN1 (0.57) MEN1KMT2AHDAC4ABL1RIN1
SCHEMBL14393707 0.83 KMT2A (0.62) MEN1KMT2AHDAC4ABL1RIN1
SCHEMBL23709495 0.82 KMT2A (0.69) MEN1KMT2AHDAC4ABL1RIN1
SCHEMBL5735195 0.82 MEN1 (0.55) MEN1KMT2AHDAC4ABL1RIN1
SCHEMBL8252454 0.82 KMT2A (0.72) MEN1KMT2AHDAC4ABL1RIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7786122-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-08-31 US disclosed
US-20080085894-A1 ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-04-10 US disclosed
US-7300936-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085894-A1 ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS APP, APBA1, BACE1 MEN1 3211/4885KMT2A 3511/4885HDAC4 2972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.